Research Institute of Molecular Pathology

The Research Institute of Molecular Pathology (IMP) is a basic biomedical research center sponsored largely by the pharmaceutical company Boehringer Ingelheim, and located in the Campus Vienna Biocenter (VBC). The IMP's primary goal is to conduct innovative basic research in the molecular life sciences. Over the years, the IMP has rapidly established a strong international reputation, reflected in the numerous national and international awards bestowed upon its scientists, and the many key research papers published in top-ranking scientific journals each year. The IMP attracts researchers from all over the world, almost all of whom move on after several years to leading scientific positions elsewhere in Austria or abroad. This constant turnover gives the IMP a young, dynamic and international spirit, and the flexibility to continually hire promising new scientific talents and expand its research activities into exciting new directions. Researchers at the IMP are committed to basic science, striving to unlock life's fundamental mysteries at the molecular and cellular levels.

Some content from Wikipedia, licensed under CC BY-SA

A molecular toolkit for gene silencing

The team of Johannes Zuber at the IMP in Vienna, Austria, managed to overcome remaining key limitations of RNA interference (RNAi) - a unique method to specifically shut off genes. By using an optimized design, ...

Dec 13, 2013
4.3 / 5 (3) 0

Pushing the limits of light microscopy

A team of researchers from the IMP Vienna together with collaborators from the Vienna University of Technology established a new microscopy technique which greatly enhances resolution in the third dimension. ...

Nov 29, 2013
3.8 / 5 (4) 0

A skeleton for chromosomes

Researchers at the IMP Vienna discovered that cohesin stabilizes DNA. Jan-Michael Peters and his team at the Research Institute of Molecular Pathology (IMP) found that the structure of Chromosomes is supported ...

Aug 26, 2013
4.5 / 5 (2) 0